Corcept Therapeutics Incorporated annual free cash flow for fiscal TTM was $107 million, a decrease of 24.6% from $142 million in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| Free Cash Flow (annual) | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow (FCF) | $107M | $142M | $196M | $127M | $120M | $167M | $151M | $135M | $115M | $61M | $18M | $3M | ($28M) | ($37M) | ($36M) | ($27M) | ($22M) | ($18M) | ($18M) | ($11M) | ($25M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Free Cash Flow (quarterly) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Free Cash Flow (FCF) | $31M | ($17M) | $38M | $54M | $44M | $5M | $59M | $72M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More CORT metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · EBITDA · Shares Outstanding
All CORT financial statements → Interactive CORT charts →
About TickerBase · Data methodology & sources · Privacy · Terms